PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Choucair, Khalil ^a   Ejdelman, Joshua ^a   Brimo, Fadi ^a   Aprikian, Armen ^a   Chevalier, Simone ^a   Lapointe, Jacques ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

AR; Prognosis; Prostate cancer; PTEN

Indexed keywords

ANDROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ANDROGEN RECEPTOR GENE; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DOWN REGULATION; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE GENE; PREDICTIVE VALUE; PRIMARY TUMOR; PROSTATE CANCER; RECURRENT CANCER; REGULATOR GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR GENE;

AGED; DNA COPY NUMBER VARIATIONS; FOLLOW-UP STUDIES; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTORS, ANDROGEN; SEQUENCE DELETION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84869884237     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-543     Document Type: Article

References (42)

1. Canadian Cancer Society's Steering Committee on Cancer Statistics Canadian Cancer Statistics 2011 2011, Toronto: Canadian Cancer Society, Canadian Cancer Society's Steering Committee on Cancer Statistics.
2. Bentel JM, Tilley WD. Androgen receptors in prostate cancer. J Endocrinol 1996, 151:1-11. 10.1677/joe.0.1510001, 8943763.
3. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 2009, 27:36-41. 10.1016/j.urolonc.2008.03.021, 3245883, 19111796.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520. 10.1056/NEJMoa041318, 15470214.
5. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005, 8:108-118. 10.1038/sj.pcan.4500776, 15724144.
6. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39. 10.1016/S0092-8674(00)81780-8, 9778245.
7. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003, 1:E59. 270016, 14691534.
8. Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A, van der Kwast T, Milosevic M, Yoshimoto M, Squire JA, et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009, 69:1091-1100. 10.1002/pros.20959, 19350549.
9. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007, 67:8504-8510. 10.1158/0008-5472.CAN-07-0673, 17875689.
10. McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer?. Br J Cancer 2008, 99:1296-1301. 10.1038/sj.bjc.6604680, 2570524, 18854827.
11. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian AG, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009, 218:505-513. 10.1002/path.2559, 19402094.
12. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22. 10.1016/j.ccr.2010.05.026, 3198787, 20579941.
13. Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van Gurp RJ, Stoop H, van der Kwast TH, Trapman J. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 2006, 208:699-707. 10.1002/path.1929, 16402365.
14. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, Squire JA. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007, 97:678-685. 10.1038/sj.bjc.6603924, 2360375, 17700571.
15. Yoshimoto M, Cutz JC, Nuin PA, Joshua AM, Bayani J, Evans AJ, Zielenska M, Squire JA. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006, 169:128-137. 10.1016/j.cancergencyto.2006.04.003, 16938570.
16. Bertram J, Peacock JW, Fazli L, Mui AL, Chung SW, Cox ME, Monia B, Gleave ME, Ong CJ. Loss of PTEN is associated with progression to androgen independence. Prostate 2006, 66:895-902. 10.1002/pros.20411, 16496415.
17. Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 2007, 67:6083-6091. 10.1158/0008-5472.CAN-06-4202, 17616663.
18. Wu Z, Conaway M, Gioeli D, Weber MJ, Theodorescu D. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. Prostate 2006, 66:1114-1123. 10.1002/pros.20447, 16637073.
19. Fuller CE, Schmidt RE, Roth KA, Burger PC, Scheithauer BW, Banerjee R, Trinkaus K, Lytle R, Perry A. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol 2003, 62:1118-1128.
20. Raghavan R, Balani J, Perry A, Margraf L, Vono MB, Cai DX, Wyatt RE, Rushing EJ, Bowers DC, Hynan LS, White CL. Pediatric Oligodendrogliomas: A Study of Molecular Alterations on 1p and 19q Using Fluorescence In Situ Hybridization. J Neuropathol Exp Neurol 2003, 62:530-537.
21. Bosman FT, de Goeij AF, Rousch M. Quality control in immunocytochemistry: experiences with the oestrogen receptor assay. J Clin Pathol 1992, 45:120-124. 10.1136/jcp.45.2.120, 495649, 1541691.
22. Aasmundstad TA, Haugen OA, Johannesen E, Hoe AL, Kvinnsland S. Oestrogen receptor analysis: correlation between enzyme immunoassay and immunohistochemical methods. J Clin Pathol 1992, 45:125-129. 10.1136/jcp.45.2.125, 495650, 1371776.
23. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550. 10.1073/pnas.0506580102, 1239896, 16199517.
24. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004, 101:811-816. 10.1073/pnas.0304146101, 321763, 14711987.
25. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002, 99:11890-11895. 10.1073/pnas.182376299, 129364, 12185249.
26. DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, Tibshirani R, Brown PO, Brooks JD. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol 2002, 3:RESEARCH0032. 126237, 12184806.
27. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009, 69:2912-2918. 10.1158/0008-5472.CAN-08-3667, 19339269.
28. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010, 102:678-684. 10.1038/sj.bjc.6605554, 2837564, 20104229.
29. El Sheikh SS, Romanska HM, Abel P, Domin J, el Lalani N. Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer--a pilot study. Neoplasia 2008, 10:949-953. 2517639, 18714395.
30. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995, 9:401-406. 10.1038/ng0495-401, 7795646.
31. Lin HK, Hu YC, Lee DK, Chang C. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 2004, 18:2409-2423. 10.1210/me.2004-0117, 15205473.
32. Nan B, Snabboon T, Unni E, Yuan XJ, Whang YE, Marcelli M. The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol 2003, 31:169-183. 10.1677/jme.0.0310169, 12914534.
33. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY, Chang C. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 2003, 278:50902-50907. 10.1074/jbc.M300676200, 14555644.
34. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG, Wu H. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011, 19:792-804. 10.1016/j.ccr.2011.05.006, 3157296, 21620777.
35. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011, 19:575-586. 10.1016/j.ccr.2011.04.008, 3142785, 21575859.
36. Diallo JS, Aldejmah A, Mouhim AF, Fahmy MA, Koumakpayi IH, Sircar K, Begin LR, Mes-Masson AM, Saad F. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. BJU Int 2008, 101:1302-1309. 10.1111/j.1464-410X.2008.07514.x, 18294307.
37. Schafer W, Funke PJ, Kunde D, Rausch U, Wennemuth G, Stutzer H. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations. J Urol 2006, 176:532-537. 10.1016/j.juro.2006.03.033, 16813883.
38. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 2001, 61:423-427.
39. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004, 28:928-934. 10.1097/00000478-200407000-00013, 15223964.
40. Descazeaud A, de la Taille A, Allory Y, Faucon H, Salomon L, Bismar T, Kim R, Hofer MD, Chopin D, Abbou CC, Rubin MA. Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate 2006, 66:1037-1043. 10.1002/pros.20405, 16598739.
41. Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006, 98:1420-1424. 10.1093/jnci/djj378, 17018789.
42. Lapointe J, Malhotra S, Higgins JP, Bair E, Thompson M, Salari K, Giacomini CP, Ferrari M, Montgomery K, Tibshirani R, et al. hCAP-D3 Expression Marks a Prostate Cancer Subtype With Favorable Clinical Behavior and Androgen Signaling Signature. Am J Surg Pathol 2008, 32:205-209. 10.1097/PAS.0b013e318124a865, 18223322.